目的 确定用于TYMS基因表达水平判定的临界值, 并对TYMS基因表达水平判定方法的临床指导意义进行验证。方法 通过实时荧光定量PCR技术平台及2-△Ct法计算TYMS基因相对于内参基因的表达量。将中位值作为判定TYMS基因表达水平的临界值, 并通过患者接受培美曲塞化疗的短期、长期疗效对该临界值进行验证。结果 在150例FFPE样本中, TYMS基因、内参基因同时可检出的检出率为89.3%, TYMS基因相对表达量在晚期肺腺癌患者不同年龄组中差异有统计学意义(P=0.025), 但与患者性别、癌症分型、分期及吸烟史差异均无统计学意义。TYMS基因高表达、低表达患者在接受培美曲塞化疗后的客观有效率分别为9.8%、35.4%(P<0.05)。TYMS基因高表达、低表达患者接受培美曲塞化疗的中位无进展生存时间差异有统计学意义, 分别为2.1个月、4.9个月(P=0.047);TYMS基因高表达、低表达患者中位总体生存时间差异有统计学意义, 分别为9.1个月、16.7个月(P=0.024)。结论 TYMS基因表达水平判定方法适用于判定晚期肺腺癌FFPE样本中TYMS基因表达水平等级, 有利于TYMS基因表达量检测的标准化, 且该方法可用来预测培美曲塞化疗的疗效。
Abstract
Objective To examine the relative expression of TYMS gene in 150 FFPE samples of advanced lung adenocarcinoma patients and to validate the method for differentiating TYMS gene expression levels in term of clinical significance. Methods Real time quantitative PCR and 2-△Ct method was used to detect the expression of TYMS and internal reference gene. The median value was used as the cut-off value and retrospective validation was performed including the short and long term therapeutic response towards pemetrexed based chemotherapy. Results In the 150 samples we examined, the detection rate was 89.3% when both the TYMS and the internal reference gene were successfully amplified. TYMS expression was significantly correlated with late stage adenocarcinoma patients’ age groups (P=0.025) but not significantly correlated with patients’ gender, histology, stage or smoking history (P＞0.05). The ORR (Objective response rate) in TYMS high and low expression groups was 9.8% and 35.4%, respectively (P<0.05). The median progression free survival time in TYMS high and low expression group was 2.1 and 4.9 months, respectively (P=0.047). The median overall survival time in TYMS high and low expression group was 9.1 and 16.7 months, respectively (P=0.024). Conclusions The method for differentiating TYMS gene expression levels in the present study is suitable in late stage adenocarcinoma patients and sheds light on the standardization of TYMS expression detection. This method can also be used to predict the therapeutic efficiency of pemetrexed chemotherapy.
关键词
肺腺癌 /
TYMS基因 /
表达量 /
临界值
Key words
lung adenocarcinoma /
TYMS /
expression /
cut-off value
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA: A Cancer Journal for Clinicians, 2011, 61(2): 69-90.
[2] Muhsin M, Gricks C, Kirkpatrick P. Pemetrexed disodium[J]. Nat Rev Drug Discov, 2004, 3(10): 825-826.
[3] 李兰芳, 胡 歌, 刘 贤, 等.吉西他滨联合培美曲塞治疗晚期非小细胞肺癌[J]. 实用肿瘤杂志, 2010, (5): 578-580.
[4] 张雪艳, 黄艾弥, 白 皓, 等.培美曲塞单药或联合化疗治疗晚期复发性非小细胞肺癌68例分析[J]. 中国癌症杂志, 2009, 26(2): 118-121.
[5] Rouquette I, Mazieres J. A brief overview of a lung cancer biomarker: thymidylate synthase[J]. Revue des maladies respiratoires, 2011, 28(6):773-777.
[6] 李 艳, 章明放, 郭雪西, 等. 胃腺癌中P-gp、ToPoⅡ、GSTπ、MGMT和TS的表达及意义[J]. 临床与实验病理学杂志, 2011, 23(11):45-48.
[7] 郑巧荣, 崔金全. 宫颈上皮内瘤变及宫颈癌中TS、PCNA的表达及其意义[J]. 中国妇幼保健, 2011, 21(7):125-127.
[8] 黄慧敏, 李惠翔, 张 红, 等. RNAi对人乳腺癌MCF-7细胞E2F1、TS基因表达的抑制作用[J]. 山东医药, 2008, 43(1):14-15.
[9] 李世拥, 于 波, 安 萍, 等.胸苷酸合成酶基因表达与结肠直肠癌复发的关系及其临床意义[J]. 中华外科杂志, 2000, 52(10):60-62.
[10] Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer[J]. Cancer science, 2010, 101(1):161-166.
[11] Roe O D, Szulkin A, Anderssen E, et al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma[J]. PloS one, 2012, 7(8): e40521.
[12] Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer[J]. British J cancer, 2011, 104(10): 1594-1601.
[13] Mairinger F, Vollbrecht C, Halbwedl I, et al. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma[J]. J Thorac Oncol, 2013, 8(5): 644-653
[14] Zucali P A, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin[J]. Clinical Cancer Research, 2011, 17(8): 2581-2590.
[15] Bepler G, Sommers K E, Cantor A, et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer[J]. J Thorac Oncol, 2008, 3(10):1112-1118.
[16] Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J]. J Clini Oncol, 2001, 19(23):4298-4304.
